 | • レポートコード：MRC2301A061 • 出版社/出版日：360iResearch / 2022年10月 • レポート形態：英語、PDF、243ページ • 納品方法：Eメール（受注後2-3日） • 産業分類：医薬品 |
| Single User（1名利用、印刷可） | ￥742,350 (USD4,949) | ▷ お問い合わせ |
| Enterprise License（企業利用、印刷可） | ￥1,492,350 (USD9,949) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 360iResearch社の本調査レポートでは、2021年に3,065.22百万ドルであった世界の卵巣がん治療薬市場規模が、2022年に3,478.22百万ドルに到達し、2027年まで年平均13.65%で成長して6,605.41百万ドルまで拡大すると予測しています。本レポートは、卵巣がん治療薬の世界市場について総合的・多面的に調査・分析し、序論、調査方法、エグゼクティブサマリー、市場概要、市場インサイト、治療クラス別（血管新生阻害薬、PARP阻害薬、PD-L1阻害薬）分析、モダリティ別（化学治療、ホルモン治療、標的治療）分析、治療薬別（アバスチン、カルボプラチン、ドキシル、リムパーザ、ヨンデリス）分析、地域別（南北アメリカ、アメリカ、カナダ、ブラジル、アジア太平洋、日本、中国、インド、韓国、台湾、ヨーロッパ/中東/アフリカ、イギリス、ドイツ、フランス、ロシア、その他）分析、競争状況、企業情報などを以下の構成でまとめております。本資料には、Allergan plc、AstraZeneca Plc、Boehringer Ingelheim、Clovis Oncology、F. Hoffmann-La Roche AG、Johnson & Johnson、Merck & Co., Inc.、Pfizer, Incnなどの企業情報が含まれています。 ・序論 ・調査方法 ・エグゼクティブサマリー ・市場概要 ・市場インサイト ・世界の卵巣がん治療薬市場規模：治療クラス別 - 血管新生阻害薬の市場規模 - PARP阻害薬の市場規模 - PD-L1阻害薬の市場規模 ・世界の卵巣がん治療薬市場規模：モダリティ別 - 化学治療における市場規模 - ホルモン治療における市場規模 - 標的治療における市場規模 ・世界の卵巣がん治療薬市場規模：治療薬別 - アバスチンにおける市場規模 - カルボプラチンにおける市場規模 - ドキシルにおける市場規模 - リムパーザにおける市場規模 - ヨンデリスにおける市場規模 ・世界の卵巣がん治療薬市場規模：地域別 - 南北アメリカの卵巣がん治療薬市場規模 アメリカの卵巣がん治療薬市場規模 カナダの卵巣がん治療薬市場規模 ブラジルの卵巣がん治療薬市場規模 … - アジア太平洋の卵巣がん治療薬市場規模 中国の卵巣がん治療薬市場規模 インドの卵巣がん治療薬市場規模 韓国の卵巣がん治療薬市場規模 台湾の卵巣がん治療薬市場規模 … - ヨーロッパ/中東/アフリカの卵巣がん治療薬市場規模 イギリスの卵巣がん治療薬市場規模 ドイツの卵巣がん治療薬市場規模 フランスの卵巣がん治療薬市場規模 ロシアの卵巣がん治療薬市場規模 … - その他地域の卵巣がん治療薬市場規模 ・競争状況 ・企業情報 |
The Global Ovarian Cancer Drugs Market size was estimated at USD 3,065.22 million in 2021 and expected to reach USD 3,478.22 million in 2022, and is projected to grow at a CAGR 13.65% to reach USD 6,605.41 million by 2027.
Market Statistics:
The report provides market sizing and forecast across 7 major currencies – USD, EUR, JPY, GBP, AUD, CAD, and CHF. It helps organization leaders make better decisions when currency exchange data is readily available. In this report, the years 2018 and 2020 are considered as historical years, 2021 as the base year, 2022 as the estimated year, and years from 2023 to 2027 are considered as the forecast period.
Market Segmentation & Coverage:
This research report categorizes the Ovarian Cancer Drugs to forecast the revenues and analyze the trends in each of the following sub-markets:
Based on Therapeutics Class, the market was studied across Angiogenesis Inhibitors, PARP Inhibitors, and PD-L1 Inhibitors.
Based on Modality, the market was studied across Chemotherapy, Hormonal Therapy, and Targeted Therapy.
Based on Drugs, the market was studied across Avastin, Carboplatin, Doxil, Lynparza, and Yondelis.
Based on Region, the market was studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.
Cumulative Impact of COVID-19:
COVID-19 is an incomparable global public health emergency that has affected almost every industry, and the long-term effects are projected to impact the industry growth during the forecast period. Our ongoing research amplifies our research framework to ensure the inclusion of underlying COVID-19 issues and potential paths forward. The report delivers insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The updated study provides insights, analysis, estimations, and forecasts, considering the COVID-19 impact on the market.
Cumulative Impact of 2022 Russia Ukraine Conflict:
We continuously monitor and update reports on political and economic uncertainty due to the Russian invasion of Ukraine. Negative impacts are significantly foreseen globally, especially across Eastern Europe, European Union, Eastern & Central Asia, and the United States. This contention has severely affected lives and livelihoods and represents far-reaching disruptions in trade dynamics. The potential effects of ongoing war and uncertainty in Eastern Europe are expected to have an adverse impact on the world economy, with especially long-term harsh effects on Russia.This report uncovers the impact of demand & supply, pricing variants, strategic uptake of vendors, and recommendations for Ovarian Cancer Drugs market considering the current update on the conflict and its global response.
Competitive Strategic Window:
The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies to help the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. It describes the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth during a forecast period.
FPNV Positioning Matrix:
The FPNV Positioning Matrix evaluates and categorizes the vendors in the Ovarian Cancer Drugs Market based on Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.
Market Share Analysis:
The Market Share Analysis offers the analysis of vendors considering their contribution to the overall market. It provides the idea of its revenue generation into the overall market compared to other vendors in the space. It provides insights into how vendors are performing in terms of revenue generation and customer base compared to others. Knowing market share offers an idea of the size and competitiveness of the vendors for the base year. It reveals the market characteristics in terms of accumulation, fragmentation, dominance, and amalgamation traits.
Competitive Scenario:
The Competitive Scenario provides an outlook analysis of the various business growth strategies adopted by the vendors. The news covered in this section deliver valuable thoughts at the different stage while keeping up-to-date with the business and engage stakeholders in the economic debate. The competitive scenario represents press releases or news of the companies categorized into Merger & Acquisition, Agreement, Collaboration, & Partnership, New Product Launch & Enhancement, Investment & Funding, and Award, Recognition, & Expansion. All the news collected help vendor to understand the gaps in the marketplace and competitor’s strength and weakness thereby, providing insights to enhance product and service.
Company Usability Profiles:
The report profoundly explores the recent significant developments by the leading vendors and innovation profiles in the Global Ovarian Cancer Drugs Market, including Allergan plc, AstraZeneca Plc, Boehringer Ingelheim, Clovis Oncology, F. Hoffmann-La Roche AG, Johnson & Johnson, Merck & Co., Inc., Pfizer, Incn, Syndax Pharmaceuticals, Inc., Tesaro, and Zeltia Group.
The report provides insights on the following pointers:
1. Market Penetration: Provides comprehensive information on the market offered by the key players
2. Market Development: Provides in-depth information about lucrative emerging markets and analyze penetration across mature segments of the markets
3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments
4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players
5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments
The report answers questions such as:
1. What is the market size and forecast of the Global Ovarian Cancer Drugs Market?
2. What are the inhibiting factors and impact of COVID-19 shaping the Global Ovarian Cancer Drugs Market during the forecast period?
3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Ovarian Cancer Drugs Market?
4. What is the competitive strategic window for opportunities in the Global Ovarian Cancer Drugs Market?
5. What are the technology trends and regulatory frameworks in the Global Ovarian Cancer Drugs Market?
6. What is the market share of the leading vendors in the Global Ovarian Cancer Drugs Market?
7. What modes and strategic moves are considered suitable for entering the Global Ovarian Cancer Drugs Market?
1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Rising incidences of ovarian cancer around the globe
5.1.1.2. Increasing geriatric population of women around the world
5.1.1.3. Adoption of novel drugs and strong developmental pipeline
5.1.2. Restraints
5.1.2.1. Adverse impact of cancer drugs on the human body
5.1.3. Opportunities
5.1.3.1. Rising funding in the healthcare industry by the government in developing countries
5.1.3.2. Developments in ovarian cancer drugs in emerging economies
5.1.4. Challenges
5.1.4.1. Cost associated with the treatment of ovarian cancer is high
5.2. Cumulative Impact of COVID-19
6. Ovarian Cancer Drugs Market, by Therapeutics Class
6.1. Introduction
6.2. Angiogenesis Inhibitors
6.3. PARP Inhibitors
6.4. PD-L1 Inhibitors
7. Ovarian Cancer Drugs Market, by Modality
7.1. Introduction
7.2. Chemotherapy
7.3. Hormonal Therapy
7.4. Targeted Therapy
8. Ovarian Cancer Drugs Market, by Drugs
8.1. Introduction
8.2. Avastin
8.3. Carboplatin
8.4. Doxil
8.5. Lynparza
8.6. Yondelis
9. Americas Ovarian Cancer Drugs Market
9.1. Introduction
9.2. Argentina
9.3. Brazil
9.4. Canada
9.5. Mexico
9.6. United States
10. Asia-Pacific Ovarian Cancer Drugs Market
10.1. Introduction
10.2. Australia
10.3. China
10.4. India
10.5. Indonesia
10.6. Japan
10.7. Malaysia
10.8. Philippines
10.9. Singapore
10.10. South Korea
10.11. Taiwan
10.12. Thailand
10.13. Vietnam
11. Europe, Middle East & Africa Ovarian Cancer Drugs Market
11.1. Introduction
11.2. Denmark
11.3. Egypt
11.4. Finland
11.5. France
11.6. Germany
11.7. Israel
11.8. Italy
11.9. Netherlands
11.10. Nigeria
11.11. Norway
11.12. Poland
11.13. Qatar
11.14. Russia
11.15. Saudi Arabia
11.16. South Africa
11.17. Spain
11.18. Sweden
11.19. Switzerland
11.20. Turkey
11.21. United Arab Emirates
11.22. United Kingdom
12. Competitive Landscape
12.1. FPNV Positioning Matrix
12.1.1. Quadrants
12.1.2. Business Strategy
12.1.3. Product Satisfaction
12.2. Market Ranking Analysis, By Key Player
12.3. Market Share Analysis, By Key Player
12.4. Competitive Scenario
12.4.1. Merger & Acquisition
12.4.2. Agreement, Collaboration, & Partnership
12.4.3. New Product Launch & Enhancement
12.4.4. Investment & Funding
12.4.5. Award, Recognition, & Expansion
13. Company Usability Profiles
13.1. Allergan plc
13.1.1. Business Overview
13.1.2. Key Executives
13.1.3. Product & Services
13.2. AstraZeneca Plc
13.2.1. Business Overview
13.2.2. Key Executives
13.2.3. Product & Services
13.3. Boehringer Ingelheim
13.3.1. Business Overview
13.3.2. Key Executives
13.3.3. Product & Services
13.4. Clovis Oncology
13.4.1. Business Overview
13.4.2. Key Executives
13.4.3. Product & Services
13.5. F. Hoffmann-La Roche AG
13.5.1. Business Overview
13.5.2. Key Executives
13.5.3. Product & Services
13.6. Johnson & Johnson
13.6.1. Business Overview
13.6.2. Key Executives
13.6.3. Product & Services
13.7. Merck & Co., Inc.
13.7.1. Business Overview
13.7.2. Key Executives
13.7.3. Product & Services
13.8. Pfizer, Incn
13.8.1. Business Overview
13.8.2. Key Executives
13.8.3. Product & Services
13.9. Syndax Pharmaceuticals, Inc.
13.9.1. Business Overview
13.9.2. Key Executives
13.9.3. Product & Services
13.10. Tesaro
13.10.1. Business Overview
13.10.2. Key Executives
13.10.3. Product & Services
13.11. Zeltia Group
13.11.1. Business Overview
13.11.2. Key Executives
13.11.3. Product & Services
14. Appendix
14.1. Discussion Guide
14.2. License & Pricing